Analysis

Mid-afternoon market update: Nasdaq rises 50 points, Jefferies shares drop

Toward the end of trading Wednesday, the Dow traded up 0.05% to 36,269.24 while the NASDAQ rose 0.35% to 15,205.90. The S&P also rose, gaining, 0.26% to 4,725.52.

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 63,390,870 cases with around 863,890 deaths. India confirmed a total of at least 36,070,510 cases and 484,650 deaths, while Brazil reported over 22,630,140 COVID-19 cases with 620,280 deaths. In total, there were at least 314,292,710 cases of COVID-19 worldwide with more than 5,522,840 deaths.

Leading and Lagging Sectors

Information technology shares rose 0.6% on Wednesday. Meanwhile, top gainers in the sector included Ebix, Inc. EBIX +15.26% (Get Free Alerts for EBIX), up 14% and Innodata Inc. INOD +9.47% (Get Free Alerts for INOD) up 9%.

In trading on Wednesday, health care shares fell by 0.4%.

Top Headline

The annual inflation rate in the US increased to 7% in December, notching a fresh high since June 1982, and up from 6.8% in the previous month. Analysts, however, were expecting a 7% inflation rate. The CPI rose 0.50% month-over-month during December.

Equities Trading UP

Immix Biopharma, Inc. IMMX +18.42% shares shot up 26% to $6.83 after the company announced preclinical data of its lead program, IMX-110. The data showed that IMX-110 produced a 50% response rate in first-line-therapy-resistant cancer - soft tissue sarcoma (STS) mouse study, surpassing the STS standard of care doxorubicin’s 0% response rate in the same mouse study.

Shares of Fresh Vine Wine, Inc. VINE +19.24% got a boost, shooting 44% to $8.41 after the company reported a partnership with CRAVE American Kitchen & Sushi Bar.

Immuron Limited IMRN +46.18% shares were also up, gaining 43% to $3.65. Immuron received funding of A$6.2 ($4.45) million from the U.S Department of Defense to examine a dosing regimen for Travelan more suited for use by the military.

Equities Trading DOWN

Koninklijke Philips N.V. PHG -14.68% shares tumbled 15% to $32.77 after the company provided an update on its financial performance in Q4 2021. Philips hiked the cost of its recall of ventilators and warned earnings would take a big hit from global supply chain shortages.

Shares of Jefferies Financial Group Inc. JEF -9.29% were down 11% to $36.86 after the company reported worse-than-expected Q4 sales results.

Aclaris Therapeutics, Inc. ACRS -13.61% was down, falling 14% to $11.04. Providing a R&D update, Aclaris Therapeutics said David Gordon, its chief medical officer left the company, effective Jan. 7. The company also announced update on its two Phase 2 programs that evaluate zunsemetinib in subjects with moderate to severe rheumatoid arthritis and in subjects with moderate to severe hidradenitis suppurative.

Commodities

In commodity news, oil traded up 2% to $82.83, while gold traded up 0.3% to $1,824.20.

Silver traded up 1.5% Wednesday to $23.155 while copper rose 3.8% to $4.5990.

Euro zone

European shares closed higher today. The eurozone’s STOXX 600 gained 0.65%, London’s FTSE 100 rose 0.71%, while Spain’s IBEX 35 Index rose 0.16%. The German DAX gained 0.43%, French CAC 40 climbed 0.75% and Italy’s FTSE MIB Index gained 0.65%.

Wholesale price inflation in Germany slowed to 16.1% in December from a record level of 16.6% in the previous month.

Economics

The annual inflation rate in the US increased to 7% in December, notching a fresh high since June 1982, and up from 6.8% in the previous month. Analysts, however, were expecting a 7% inflation rate. The CPI rose 0.50% month-over-month during December.

US crude-oil inventories dropped 4.6 million barrels last week, the EIA said.

The Federal Open Market Committee released its Beige Book report.

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.


RELATED CONTENT

Loading ...



Copyright © 2024 FOREXSTREET S.L., All rights reserved.